The Coverage Wall Is Still Standing in 2026
A new report from The Daily Northwestern highlights a Chicago-based foundation stepping in to fund ketamine treatment for patients who can't afford to wait for insurers to catch up. The piece underscores a reality that thousands of depression patients are navigating right now: ketamine is clinically compelling, increasingly mainstream, and still largely unaffordable without out-of-pocket spending or philanthropic help.
Most major U.S. insurers continue to classify ketamine infusion therapy as experimental for psychiatric indications, leaving patients with treatment-resistant depression (TRD) and other mood disorders to foot bills that can run $400–$800 per infusion session — with standard protocols calling for six sessions in two to three weeks. That's a $2,400–$4,800 upfront commitment before any maintenance dosing begins. For a large share of Americans, that math simply doesn't work.
The Chicago foundation profiled in the article is one of a small but growing number of nonprofit intermediaries trying to bridge that gap. Their model — direct patient grants and partnerships with licensed ketamine providers — represents a workaround, not a solution. The underlying insurance problem remains unresolved, and demand for subsidized access far outpaces available funding.
Where Oral Ketamine Tablets Fit Into This Access Problem
This is precisely the context in which oral ketamine — including tablets and troches prescribed through telehealth or outpatient psychiatric practices — has expanded so rapidly. When IV infusion is priced out of reach and insurers won't budge, patients and prescribers have increasingly turned to compounded oral formulations as a cost-accessible middle path.
Here's how the formats compare on the access dimension specifically:
- IV infusions: Highest bioavailability (roughly 100%), fastest onset, strongest acute dissociative effect — and the most expensive, most logistically demanding option. Requires a clinic visit, monitoring, and a driver home.
- Intramuscular (IM) injections: Also clinic-administered, somewhat lower cost than IV, similar access barriers.
- Sublingual troches or tablets: Compounded at a pharmacy, taken at home, and priced significantly lower — often in the $150–$350/month range depending on dosing protocol and provider. Bioavailability is lower than IV (roughly 20–30% for sublingual absorption), but for maintenance and lower-acuity protocols, this is often clinically appropriate.
- Oral swallowed tablets: Bioavailability drops further when ketamine passes through the GI tract (first-pass metabolism reduces it to around 16–20%), but standardized dosing and ease of administration make this format appealing for certain patients and prescribers, particularly in lower-dose protocols or as part of a step-down from infusion.
The practical implication: oral ketamine doesn't replicate an infusion. But for patients who need an accessible, repeatable, home-based option — especially for maintenance after an initial infusion series, or as a first-line trial in patients who aren't candidates for or can't afford IV — it fills a genuine clinical and financial gap.
Key Takeaway on Dosing and Absorption
Oral and sublingual ketamine tablets have meaningfully lower bioavailability than IV infusions. This isn't a flaw — it's a known pharmacological reality that prescribers account for when setting doses. If you're transitioning from infusions to oral tablets, expect your dose in milligrams to look quite different. Never self-adjust dosing based on infusion equivalents without guidance from your prescribing provider.
What the Insurance Landscape Means for Tablet Users Specifically
For patients already using or considering oral ketamine tablets, the insurance story has a slightly different shape than it does for infusion patients. A small number of insurers — and more commonly, FSA/HSA accounts — will reimburse for compounded ketamine prescriptions when accompanied by appropriate documentation. This is worth exploring proactively with your provider and your plan administrator.
The broader policy environment is also shifting, if slowly. Several state legislatures have introduced or passed bills requiring insurers to cover FDA-approved esketamine (Spravato), which is administered as a nasal spray in certified clinical settings. While compounded oral ketamine sits in a different regulatory category than Spravato, expanded coverage precedents for one form of ketamine treatment tend to create downstream pressure on insurers to revisit coverage policies more broadly.
The Chicago foundation's model also points toward a near-term opportunity: as oral and at-home ketamine formats mature, patient assistance programs and grant structures may become more viable for this format than for infusions, simply because the per-patient cost is lower and the logistics of home-based treatment are easier to support at scale.
The Bottom Line for Patients Navigating This Now
The insurance gap isn't closing quickly. For patients with treatment-resistant depression who are weighing their options in 2026, oral ketamine tablets represent a clinically grounded, cost-accessible pathway that doesn't require waiting for insurer policy to catch up with the evidence. Understanding what oral formats can and can't do — and working with a provider who sets expectations clearly around dosing, absorption, and treatment goals — is the most practical way to make use of what's available right now.
Read the original reporting on the Chicago foundation's work at The Daily Northwestern.
Share